Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
RN
TransCode Therapeutics, Inc. Common Stock
RNAZ
Volume
28.75K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
RN
RNAZ
RN
TransCode Therapeutics, Inc. Common Stock
RNAZ
News
·
Checkpoint Inhibitors Competitive Landscape Report 2026: Comprehensive Insights About 50+ Companies and 60+ Drugs
Mkt Cap
$30.5M
Volume
28.75K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Insider
Filings
Checkpoint Inhibitors Competitive Landscape Report 2026: Comprehensive Insights About 50+ Companies and 60+ Drugs
A comprehensive market report on checkpoint inhibitors covering 50+ companies and 60+ drugs in oncology. The report highlights key players like Bristol Myers Squibb, Genentech, and emerging companies such as OncoC4 and Transcode Therapeutics, with analysis of marketed therapies, pipeline products, and recent industry collaborations and acquisitions in the immuno-oncology space.
GlobeNewswire Inc. · Feb 18, 2026
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
TransCode Therapeutics (NASDAQ: RNAZ) announced the appointment of Jack E. Stover to its Board of Directors. Stover brings over 30 years of executive leadership experience in life sciences, drug development, and capital formation. He will join the Audit and Nominating Committees as the company advances its RNA and immuno-oncology pipeline for cancer treatment.
Benzinga · Dec 22, 2025
TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout
TransCode Therapeutics announced the acquisition of Polynoma LLC, a biotechnology firm focused on immuno-oncology, and received a $25 million strategic investment from CK Life Sciences. The deal includes stock issuance and will support the advancement of TransCode's microRNA-based therapeutic into Phase 2 clinical trials.
Benzinga · Oct 8, 2025
US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert
U.S. stock futures fell on Monday after a nine-day winning streak on the S&P 500 index. Investors will keep an eye on the Federal Reserve's decision on interest rates this week. Analysts say any de-escalation in trade tensions should be positive for the economy and financial markets.
Benzinga · May 5, 2025
Why Transcode Therapeutics (RNAZ) Stock Is Down 60% - Benzinga
Transcode Therapeutics (RNAZ) stock is trading 62% lower after the company announced the pricing of a public offering of 10 million shares at $0.30 per share, aiming to raise $3 million. The funds will be used for product development, including clinical trials for their lead therapeutic candidate.
Benzinga · Jul 23, 2024
Beat the Market Like Zacks: Goldman Sachs, Micron, Amgen in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Zacks Investment Research · Jun 10, 2024
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
GlobeNewswire Inc. · Jun 10, 2024
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
GlobeNewswire Inc. · May 29, 2024
Successful Penny Stocks Trader Tips, 3 To Use
Can these tips help you to make money trading penny stocks? The post Successful Penny Stocks Trader Tips, 3 To Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks · May 12, 2024
TransCode Therapeutics Reports 2023 Results; Provides Business Update
TransCode Therapeutics Reports 2023 Results; Provides Business Update
GlobeNewswire Inc. · Apr 3, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
RN
RNAZ
TransCode Therapeutics, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
RNAZ
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any RNAZ yet.
Related Tickers
Earnings